Table 1.
Clinical Characteristics of COVID-19 Patients with Cancer
| No. | Study Details | Country | Sample Size | Median Age |
No. of Cancer Patients | No. of Deaths (%) | Most Common Cancer |
|---|---|---|---|---|---|---|---|
| 1 | COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study79 | Eight Countries | 200 | 68·0(61·8–75·0) | 200 | 66(33%) | |
| 2 | Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study80 | China | 205 | 63 (56–70) | 205 | 40(19%) | Breast cancer |
| 3 | Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China26 | China | 28 | 65 (56.0–70.0) | 28 | 8(28.5%) | Lung cancer |
| 4 | Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study81 | China | 274 | 62.0 (44.0–70.0) | 7 (3%) | 5(1.8%) | - |
| 5 | Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort82 | U. K | 92 | 79.0 (59.0–82.0) | 20(21%) | 3(3.3%) | - |
| 6 | COVID-19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China83 | China | 116 | 54.0 (38.0–69.0) | 12(10.3%) | - | - |
| 7 | Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study84 | China | 204 | 52.9 (SD±16) | 13(6.3%) | - | - |
| 8 | Cancer in intensive care unit patients with COVID-1985 | Russia | 1307 | 66 | 31 (2.4%) | - | Breast cancer |
| 9 | COVID-19 with Different Severities: A Multicenter Study of Clinical Features86 | China | 476 | 53 | 12 (2.5%) | - | - |